Avaleht › Ülekaalulisus › Louisiana
Ülekaalulisus kliinilised uuringud osariigis Louisiana
23 uuringut haiguse Ülekaalulisus jaoks otsivad osalejaid osariigis Louisiana.
Linnad osariigis Louisiana
- Baton Rouge10 uuringut
- New Orleans5 uuringut
- Shreveport4 uuringut
- Monroe4 uuringut
- Metairie3 uuringut
- Lafayette3 uuringut
Ametlik uuringutekst (inglise keeles)
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Pennington Biomed Res Ctr, Baton Rouge
VärbamineFaas 3
Vanused 8–18 · Kõik sood · Uuendatud 30. sept 2026 · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- BRCR Global Louisiana, Gretna
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 28. sept 2026 · NCT07837973A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Southern Clin Research, Zachary
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 28. sept 2026 · NCT07668414A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Pennington Biomedical Research Center, Baton Rouge
- IMA Clinical Research Monroe-Main, Monroe
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 28. sept 2026 · NCT07794579Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
VärbamineFaas 3
Vanused 18–70 · Kõik sood · Uuendatud 24. sept 2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Velocity Clinical Research, Lafayette
VärbamineFaas 3
Vanused 6–17 · Kõik sood · Uuendatud 24. sept 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
VärbamineFaas 3
Vanused 18–70 · Kõik sood · Uuendatud 24. sept 2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Clinical Trials Management, LLC d/b/a Flourish Research, Metairie
- IMA Clinical Research Monroe - Armand, Monroe
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07282600A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- IMA Clinical Research Monroe - Armand, Monroe
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07392190A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Monroe
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07784270A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Care Access - Shreveport 2, Shreveport
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07369011Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Cardiovascular Associates Research, LLC, Covington
- Tandem Clinical Research - Marrero, Marrero
VärbamineFaas 3
Vanused 45–99 · Kõik sood · Uuendatud 22. sept 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Care Access - Lake Charles (Bayou Pines), Lake Charles
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07321886Impact of Lean Pork on Endothelial Function in Perimenopause
- Pennington Biomedical Research Center, Baton Rouge
VärbamineTerved vabatahtlikud oodatud
Vanused 40–55 · Naised · Uuendatud 22. sept 2026 · NCT06976112A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Baton Rouge
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Baton Rouge
- AURORA-2 Clinical Site, Metairie
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Elevate Clinical Research, Lake Charles
- Nola Care Clinical Research Center, Metairie
- DelRicht Clinical Research, LLC, New Orleans
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. sept 2026 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Ascension DePaul Health, New Orleans
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. sept 2026 · NCT07351045Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Shreveport
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 3. sept 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Velocity Clinical Research - Baton Rouge, Baton Rouge
- Tandem Clinical Research - Marrero, Marrero
VärbamineFaas 3
Vanused 18–99 · Kõik sood · Uuendatud 3. sept 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Pennington Biomedical Research Center, Baton Rouge
VärbamineFaas 3
Vanused 18–99 · Kõik sood · Uuendatud 27. aug 2026 · NCT07575399Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Baton Rouge
VärbamineFaas 3
Vanused 18–79 · Kõik sood · Uuendatud 10. aug 2026 · NCT07654361Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding
- Pennington Biomedical Research Center, Baton Rouge
VärbamineTerved vabatahtlikud oodatud
Vanused 18–42 · Kõik sood · Uuendatud 8. apr 2026 · NCT04583514Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.